Literature DB >> 22477298

Inflammation and platelet activation in peripheral arterial occlusive disease.

Martina Montagnana1, Cristiano Fava, Enrico Arosio, Maurizio Degan, Rosa Maria Tommasoli, Sergio De Marchi, Pietro Delva, Roberta Spadaro, Gian Cesare Guidi, Alessandro Lechi, Clara Lechi Santonastaso, Pietro Minuz.   

Abstract

OBJECTIVES: Epidemiological evidence indicates that inflammation accompanies the progression of atherosclerosis. The aim of the present cross-sectional study was to define relationships between platelet activation and inflammation in patients with mild to severe (stages II to IV) peripheral arterial occlusive disease (PAOD) and matched controls. The effect of chronic administration of low-dose acetylsalicylic acid was investigated.
METHODS: Subjects were studied on a single occasion. C-reactive protein (CRP) and two indexes of in vivo platelet activation were measured - the urinary excretion of 11-dehydrothromboxane (TX) B(2) by immunoassay and circulating platelet-monocyte aggregates (PMAs) by flow cytometry.
RESULTS: Plasma PMAs and urinary 11-dehydro-TXB(2) were significantly increased in PAOD patients compared with controls (P<0.01 for all). A positive correlation between 11-dehydro-TXB(2) and CRP was found in the study population (r(s)=0.63, P<0.001). Using logistic regression analysis, CRP was the only independent correlate of 11-dehydro-TXB(2) (β(CRP)=11.9, P<0.01), whereas only the presence of PAOD was an independent predictor of high PMA levels (β(PAOD)=13.7, P=0.001). Chronic administration of acetylsalicylic acid reduced 11-dehydro-TXB(2), but not PMA and CRP.
CONCLUSIONS: There is evidence that platelet activation in patients with PAOD is related to the vascular disease and is dependent on the severity of inflammation.

Entities:  

Year:  2007        PMID: 22477298      PMCID: PMC2733025          DOI: 10.1055/s-0031-1278255

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  25 in total

1.  C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study.

Authors:  Irene M Van Der Meer; Moniek P M De Maat; A Elisabeth Hak; Amanda J Kiliaan; Antonio Iglesias Del Sol; Deirdre A M Van Der Kuip; Rogier L G Nijhuis; Albert Hofman; Jacqueline C M Witteman
Journal:  Stroke       Date:  2002-12       Impact factor: 7.914

2.  Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines.

Authors:  R Cifkova; S Erdine; R Fagard; C Farsang; A M Heagerty; W Kiowski; S Kjeldsen; T Lüscher; J M Mallion; G Mancia; N Poulter; K H Rahn; J L Rodicio; L M Ruilope; P van Zwieten; B Waeber; B Williams; A Zanchetti
Journal:  J Hypertens       Date:  2003-10       Impact factor: 4.844

3.  Standards of medical care in diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

Review 4.  Platelets in atherothrombosis.

Authors:  David A Vorchheimer; Richard Becker
Journal:  Mayo Clin Proc       Date:  2006-01       Impact factor: 7.616

5.  Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E.

Authors:  Yuqing Huo; Andreas Schober; S Bradley Forlow; David F Smith; Matthew Craig Hyman; Steffen Jung; Dan R Littman; Christian Weber; Klaus Ley
Journal:  Nat Med       Date:  2002-12-16       Impact factor: 53.440

6.  Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay.

Authors:  M Feldman; I Jialal; S Devaraj; B Cryer
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

7.  Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.

Authors:  Ute Klinkhardt; Rupert Bauersachs; Jan Adams; Jochen Graff; Edeltraud Lindhoff-Last; Sebastian Harder
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

8.  Persistent systemic inflammation in unstable angina is largely unrelated to the atherothrombotic burden.

Authors:  Claudia Monaco; Elisabetta Rossi; Diego Milazzo; Franco Citterio; Francesca Ginnetti; Giuseppe D'Onofrio; Domenico Cianflone; Filippo Crea; Luigi M Biasucci; Attilio Maseri
Journal:  J Am Coll Cardiol       Date:  2005-01-18       Impact factor: 24.094

9.  Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: the Rotterdam Study.

Authors:  Irene M van der Meer; Moniek P M de Maat; Michiel L Bots; Monique M B Breteler; John Meijer; Amanda J Kiliaan; Albert Hofman; Jacqueline C M Witteman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-05-01       Impact factor: 8.311

10.  Lack of significant effect of low doses of aspirin on the concentrations of C-reactive protein in a group of individuals with atherothrombotic risk factors and vascular events.

Authors:  Ori Rogowski; Itzhak Shapira; Einor Ben Assayag; Nathan M Bornstein; Sharon Toker; Samuel Melamed; Arie Shirom; Shlomo Berliner
Journal:  Blood Coagul Fibrinolysis       Date:  2006-01       Impact factor: 1.276

View more
  2 in total

1.  Protein-engineered hydrogels enhance the survival of induced pluripotent stem cell-derived endothelial cells for treatment of peripheral arterial disease.

Authors:  Abbygail A Foster; Ruby E Dewi; Lei Cai; Luqia Hou; Zachary Strassberg; Cynthia A Alcazar; Sarah C Heilshorn; Ngan F Huang
Journal:  Biomater Sci       Date:  2018-02-27       Impact factor: 6.843

Review 2.  The Biochemical Markers Associated with the Occurrence of Coronary Spasm.

Authors:  Liang Li; Yong-Ping Jin; Shu-Dong Xia; Chao Feng
Journal:  Biomed Res Int       Date:  2019-09-17       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.